Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model

Hepatocellular carcinoma (HCC) is a lethal malignancy with high mortality and poor prognosis. Oncogenic transcription factor Late SV40 Factor (LSF) plays an important role in promoting HCC. A small molecule inhibitor of LSF, Factor Quinolinone Inhibitor 1 (FQI1), significantly inhibited human HCC xe...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajasekaran, Devaraja, Siddiq, Ayesha, Willoughby, Jennifer L.S., Biagi, Jessica M., Christadore, Lisa M., Yunes, Sarah A., Gredler, Rachel, Jariwala, Nidhi, Robertson, Chadia L., Akiel, Maaged A., Shen, Xue-Ning, Subler, Mark A., Windle, Jolene J., Schaus, Scott E., Fisher, Paul B., Hansen, Ulla, Sarkar, Devanand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694900/
https://www.ncbi.nlm.nih.gov/pubmed/26313006
_version_ 1782407548893134848
author Rajasekaran, Devaraja
Siddiq, Ayesha
Willoughby, Jennifer L.S.
Biagi, Jessica M.
Christadore, Lisa M.
Yunes, Sarah A.
Gredler, Rachel
Jariwala, Nidhi
Robertson, Chadia L.
Akiel, Maaged A.
Shen, Xue-Ning
Subler, Mark A.
Windle, Jolene J.
Schaus, Scott E.
Fisher, Paul B.
Hansen, Ulla
Sarkar, Devanand
author_facet Rajasekaran, Devaraja
Siddiq, Ayesha
Willoughby, Jennifer L.S.
Biagi, Jessica M.
Christadore, Lisa M.
Yunes, Sarah A.
Gredler, Rachel
Jariwala, Nidhi
Robertson, Chadia L.
Akiel, Maaged A.
Shen, Xue-Ning
Subler, Mark A.
Windle, Jolene J.
Schaus, Scott E.
Fisher, Paul B.
Hansen, Ulla
Sarkar, Devanand
author_sort Rajasekaran, Devaraja
collection PubMed
description Hepatocellular carcinoma (HCC) is a lethal malignancy with high mortality and poor prognosis. Oncogenic transcription factor Late SV40 Factor (LSF) plays an important role in promoting HCC. A small molecule inhibitor of LSF, Factor Quinolinone Inhibitor 1 (FQI1), significantly inhibited human HCC xenografts in nude mice without harming normal cells. Here we evaluated the efficacy of FQI1 and another inhibitor, FQI2, in inhibiting endogenous hepatocarcinogenesis. HCC was induced in a transgenic mouse with hepatocyte-specific overexpression of c-myc (Alb/c-myc) by injecting N-nitrosodiethylamine (DEN) followed by FQI1 or FQI2 treatment after tumor development. LSF inhibitors markedly decreased tumor burden in Alb/c-myc mice with a corresponding decrease in proliferation and angiogenesis. Interestingly, in vitro treatment of human HCC cells with LSF inhibitors resulted in mitotic arrest with an accompanying increase in CyclinB1. Inhibition of CyclinB1 induction by Cycloheximide or CDK1 activity by Roscovitine significantly prevented FQI-induced mitotic arrest. A significant induction of apoptosis was also observed upon treatment with FQI. These effects of LSF inhibition, mitotic arrest and induction of apoptosis by FQI1s provide multiple avenues by which these inhibitors eliminate HCC cells. LSF inhibitors might be highly potent and effective therapeutics for HCC either alone or in combination with currently existing therapies.
format Online
Article
Text
id pubmed-4694900
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-46949002016-01-20 Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model Rajasekaran, Devaraja Siddiq, Ayesha Willoughby, Jennifer L.S. Biagi, Jessica M. Christadore, Lisa M. Yunes, Sarah A. Gredler, Rachel Jariwala, Nidhi Robertson, Chadia L. Akiel, Maaged A. Shen, Xue-Ning Subler, Mark A. Windle, Jolene J. Schaus, Scott E. Fisher, Paul B. Hansen, Ulla Sarkar, Devanand Oncotarget Research Paper Hepatocellular carcinoma (HCC) is a lethal malignancy with high mortality and poor prognosis. Oncogenic transcription factor Late SV40 Factor (LSF) plays an important role in promoting HCC. A small molecule inhibitor of LSF, Factor Quinolinone Inhibitor 1 (FQI1), significantly inhibited human HCC xenografts in nude mice without harming normal cells. Here we evaluated the efficacy of FQI1 and another inhibitor, FQI2, in inhibiting endogenous hepatocarcinogenesis. HCC was induced in a transgenic mouse with hepatocyte-specific overexpression of c-myc (Alb/c-myc) by injecting N-nitrosodiethylamine (DEN) followed by FQI1 or FQI2 treatment after tumor development. LSF inhibitors markedly decreased tumor burden in Alb/c-myc mice with a corresponding decrease in proliferation and angiogenesis. Interestingly, in vitro treatment of human HCC cells with LSF inhibitors resulted in mitotic arrest with an accompanying increase in CyclinB1. Inhibition of CyclinB1 induction by Cycloheximide or CDK1 activity by Roscovitine significantly prevented FQI-induced mitotic arrest. A significant induction of apoptosis was also observed upon treatment with FQI. These effects of LSF inhibition, mitotic arrest and induction of apoptosis by FQI1s provide multiple avenues by which these inhibitors eliminate HCC cells. LSF inhibitors might be highly potent and effective therapeutics for HCC either alone or in combination with currently existing therapies. Impact Journals LLC 2015-07-17 /pmc/articles/PMC4694900/ /pubmed/26313006 Text en Copyright: © 2015 Rajasekaran et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Rajasekaran, Devaraja
Siddiq, Ayesha
Willoughby, Jennifer L.S.
Biagi, Jessica M.
Christadore, Lisa M.
Yunes, Sarah A.
Gredler, Rachel
Jariwala, Nidhi
Robertson, Chadia L.
Akiel, Maaged A.
Shen, Xue-Ning
Subler, Mark A.
Windle, Jolene J.
Schaus, Scott E.
Fisher, Paul B.
Hansen, Ulla
Sarkar, Devanand
Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model
title Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model
title_full Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model
title_fullStr Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model
title_full_unstemmed Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model
title_short Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model
title_sort small molecule inhibitors of late sv40 factor (lsf) abrogate hepatocellular carcinoma (hcc): evaluation using an endogenous hcc model
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694900/
https://www.ncbi.nlm.nih.gov/pubmed/26313006
work_keys_str_mv AT rajasekarandevaraja smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT siddiqayesha smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT willoughbyjenniferls smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT biagijessicam smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT christadorelisam smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT yunessaraha smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT gredlerrachel smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT jariwalanidhi smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT robertsonchadial smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT akielmaageda smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT shenxuening smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT sublermarka smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT windlejolenej smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT schausscotte smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT fisherpaulb smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT hansenulla smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel
AT sarkardevanand smallmoleculeinhibitorsoflatesv40factorlsfabrogatehepatocellularcarcinomahccevaluationusinganendogenoushccmodel